Improving pharmacological targeting of AKT in melanoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Pharmacological targeting of AKT is ineffective in melanoma despite preclinical promise.
• Genetic targeting of AKT3 or WEE1 shows efficacy in preclinical melanoma models.
• The combination of pharmacological AKT and WEE1 inhibitors has not been previously investigated for melanoma.

Purpose of the Study:

• To investigate the efficacy of combining pharmacological AKT and WEE1 inhibitors in melanoma.
• To determine if this combination enhances the therapeutic effectiveness of targeting AKT.
• To elucidate the molecular mechanisms underlying the synergistic effect.

Main Methods:

• Utilized melanoma cell cultures and preclinical animal models.
• Administered AKT inhibitors (AZD5363, MK1775) in combination with a WEE1 inhibitor (AZD5363).
• Assessed synergistic cell killing, tumor growth inhibition, and modulation of cell cycle and DNA repair pathways.

Main Results:

• The combination of AKT and WEE1 inhibitors synergistically killed cultured melanoma cells.
• Tumor growth was decreased by over 90% with the combined treatment.
• Co-targeting led to enhanced deregulation of cell cycle and DNA repair pathways via p53 and FOXM1 modulation.

Conclusions:

• Combination therapy targeting AKT and WEE1 demonstrates significant therapeutic potential in melanoma.
• This strategy overcomes the ineffectiveness of targeting AKT alone.
• Identified a specific drug combination and ratio for enhanced efficacy in melanoma treatment.